Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C8 | P10632 | 2/20 | 0.56 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.56 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | PGR | P06401 | 1/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13699137 | 1.00 | CYP2C8 (0.56) | CYP2C8CYSLTR2CYSLTR1MEN1RECQL | |
| SCHEMBL2028786 | 1.00 | CYP2C8 (0.56) | CYP2C8CYSLTR2CYSLTR1MEN1RECQL | |
| SCHEMBL13352394 | 0.92 | CYSLTR1 (0.54) | CYP2C8CYSLTR2CYSLTR1MEN1RECQL | |
| SCHEMBL20921968 | 0.90 | CYP2C8 (0.46) | CYP2C8CYSLTR2CYSLTR1MEN1RECQL | |
| SCHEMBL14113728 | 0.89 | CYP2C8 (0.45) | CYP2C8CYSLTR2CYSLTR1MEN1RECQL | |
| SCHEMBL27531782 | 0.87 | CYSLTR1 (0.58) | CYP2C8CYSLTR2CYSLTR1MEN1RECQL | |
| SCHEMBL27475143 | 0.87 | CYSLTR1 (0.58) | CYP2C8CYSLTR2CYSLTR1MEN1RECQL | |
| SCHEMBL29096087 | 0.86 | CYP2C8 (0.56) | CYP2C8CYSLTR2CYSLTR1MEN1RECQL | |
| SCHEMBL8500076 | 0.85 | CYP2C8 (0.57) | CYP2C8CYSLTR2CYSLTR1MEN1RECQL | |
| SCHEMBL8500074 | 0.85 | CYP2C8 (0.57) | CYP2C8CYSLTR2CYSLTR1MEN1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355608-A1 | TARGETING POLYCYTHEMIA VERA (PV)-INITIATING CELLS BY BLOCKING LEUKOTRIENE BINDING TO THEIR RECEPTORS | UNIVERSITY OF MASSACHUSETTS | 2023-11-09 | — | — | US | disclosed |
| EP-4010351-B1 | MONTELUKAST ESTERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | GENETIC S P A (IT) | 2023-09-27 | — | — | EP | disclosed |
| US-20220031687-A1 | SYNERGIC PHARMACEUTICAL COMBINATION OF A LEUKOTRIENE-RECEPTOR ANTAGONIST AND AN INVERSE AGONIST OF HISTAMINE HI | Amezcua Amezcua, Federico (MX) | 2022-02-03 | — | — | US | disclosed |
| US-20220016028-A1 | TOPICAL MONTELUKAST FORMULATIONS | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2022-01-20 | — | — | US | disclosed |
| US-20210393613-A1 | TOPICAL MONTELUKAST FORMULATIONS | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2021-12-23 | — | — | US | disclosed |
| US-11173117-B2 | Topical Montelukast formulations | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2021-11-16 | — | — | US | disclosed |
| US-20210236423-A1 | TOPICAL MONTELUKAST FORMULATIONS | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2021-08-05 | — | — | US | disclosed |
| US-11077104-B2 | Pharmaceutical compositions comprising POH derivatives | Neonc Technologies, Inc. (US) | 2021-08-03 | — | — | US | disclosed |
| WO-2021023751-A1 | MONTELUKAST ESTERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | GENETIC S.P.A. (IT) | 2021-02-11 | — | — | WO | disclosed |
| WO-2020245358-A1 | MONTELUKAST SALTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | GENETIC S.P.A. (IT) | 2020-12-10 | — | — | WO | disclosed |
| US-20080194825-A1 | PROCESS FOR OBTAINING MONTELUKAST | INKE, S.A. (ES) | 2008-08-14 | — | — | US | disclosed |
| WO-2008083635-A1 | A METHOD FOR THE PREPARATION OF MONTELUKAST | ZENTIVA, A.S. (CZ) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008062478-A2 | IMPROVED PROCESS FOR PURE MONTELUKAST SODIUM THROUGH PURE INTERMEDIATES AS WELL AS NOVEL AMINE SALTS | SATYANARAYANA REDDY MANNE (IN) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008058118-A2 | PREPARATION OF MONTELUKAST AND ITS SALTS | DR. REDDY'S LABORTORIES, LTD. (IN) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008009970-A2 | PROCESS FOR THE PREPARATION OF MONTELUKAST | PLIVA HRVATSKA D.O.O. (HR) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007107297-A1 | MONTELUKAST AMANTADINE SALT | SYNTHON B.V. (NL) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007057227-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | SYNTHON B.V. (NL) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007057225-A2 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | SYNTHON B.V. (NL) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007057228-A1 | A NEW INTERMEDIATE FOR MAKING MONTELUKAST AND RELATED COMPOUNDS | SYNTHON B.V. (NL) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007005965-A1 | PURIFICATION OF MONTELUKAST | TEVA PAHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11173117-B2 | Topical Montelukast formulations | CYSLTR1, CYSLTR2, SYMPK | CYP2C8 2326/4885CYSLTR2 2/4885CYSLTR1 1/4885 |
| US-20220031687-A1 | SYNERGIC PHARMACEUTICAL COMBINATION OF A LEUKOTRIENE-RECEPTOR ANTAGONIST AND AN INVERSE AGONIST OF HISTAMINE HI | HRH4, HRH2, HRH1 | CYP2C8 1575/4885CYSLTR2 5/4885CYSLTR1 6/4885 |
| US-20210393613-A1 | TOPICAL MONTELUKAST FORMULATIONS | CYSLTR1, CYSLTR2, SYMPK | CYP2C8 2537/4885CYSLTR2 2/4885CYSLTR1 1/4885 |
| US-20230355608-A1 | TARGETING POLYCYTHEMIA VERA (PV)-INITIATING CELLS BY BLOCKING LEUKOTRIENE BINDING TO THEIR RECEPTORS | CYSLTR1, LTB4R, CYSLTR2 | CYP2C8 2130/4885CYSLTR2 3/4885CYSLTR1 1/4885 |
| US-11077104-B2 | Pharmaceutical compositions comprising POH derivatives | PLIN3, PLIN5, DOHH | CYP2C8 324/4885CYSLTR2 1610/4885CYSLTR1 1885/4885 |
| US-20210236423-A1 | TOPICAL MONTELUKAST FORMULATIONS | CYSLTR1, CYSLTR2, SYMPK | CYP2C8 2326/4885CYSLTR2 2/4885CYSLTR1 1/4885 |
| US-20080194825-A1 | PROCESS FOR OBTAINING MONTELUKAST | CYSLTR1, CMA1, CYSLTR2 | CYP2C8 1922/4885CYSLTR2 3/4885CYSLTR1 1/4885 |
| US-20220016028-A1 | TOPICAL MONTELUKAST FORMULATIONS | CYSLTR1, CYSLTR2, SYMPK | CYP2C8 2537/4885CYSLTR2 2/4885CYSLTR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.